Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males
|
|
- Jasper Cox
- 6 years ago
- Views:
Transcription
1 Human Reproduction vol.8 Suppl.2 pp , 1993 Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males Jochen Schopohl Medizinische Klinik, Klinikum Innenstadt, Ziemssenstrasse 1, D Munchen 2, Germany In this study, pulsatile gonadotrophin releasing hormone () and gonadotrophin were compared for male patients with idiopathic hypothalamic hypogonadism. Thirty-six patients, 19 with this condition, and 17 with Kallmann's syndrome, were included in the study. Their mean age was 21.1 ± 3.0 years (±SD). They were divided into two groups of similar age, number and testicular volume. Pulsatile was started with 4 fig s.c. every 2 h using a portable pump and gonadotrophin with weekly i.m. injections of 3 x 2500 IU human chorionic gonadotrophin (HCG). After 8-12 weeks of HCG treatment, 150 IU human menopausal gonadotrophin (HMG) 2-4 times weekly were added and the dose of HCG reduced if necessary. Testosterone concentrations increased significantly more (P < 0.03) in the gonadotrophin group than in the group (22.5 ± 8.1 versus 16.8 ± 5.5 nmol/1). The rise in oestradiol levels was also significantly higher (P < 0.001) in the gonadotrophin group than in the group (150 ± 70 versus 88 ± 59 pmol/1). Five patients developed gynaecomastia during gonadotrophin. An increased testicular volume (TV) occurred more rapidly (P < 0.001) and was significantly more pronounced (P < 0.001) after (ATV = 8.1 ± 2.0 ml) than with gonadotrophins (ATV = 4.8 ± 1.8 ml). Sperm counts were performed in 14 patients given and in 17 patients given gonadotrophins. Ten patients given had positive sperm counts, ranging from 1.5 to 14 x 10 6 spermatozoa/ml; eight of those given gonadotrophins also developed spermatogenesis (2-26 x 10 6 /ml). The mean time period until spermatogenesis started was significantly shorter (P < 0.02) with than with gonadotrophins (12 ± 1.6 versus 20 ± 2.3 months). These results show how endocrine and exocrine testicular function can be normalized by both forms of. However, gonadotrophin has more sideeffects. Testicular growth is more pronounced with, and this also initiates spermatogenesis more rapidly than gonadotrophin. Key words: gonadotrophin//hypothalamic hypogonadism/ male/ Introduction The treatment of male idiopathic hypothalamic hypogonadism with gonadotrophins leads to good results, especially for the induction of spermatogenesis in a large number of patients (Finkel etal., 1985; Ley and Leonard, 1985; Burris etal., 1988a). Pulsatile gonadotrophin releasing hormone () can also initiate puberty and achieve spermatogenesis in these patients (Hoffman and Crowley, 1982; Morris et al., 1984; Spratt, 1986). Both forms of are effective in the treatment of male idiopathic hypothalamic hypogonadism, but only a few comparative reports exist on their respective clinical value (Liu etal., 1988a,b; Schopohl etal., 1991). The two former studies identified no difference in endocrine or exocrine testicular function after gonadotrophin or, whereas Schopohl et al. (1991) reported that had a considerable advantage over the use of gonadotrophins. The results of the latter study are described in detail here and compared with data in the literature. Materials and methods Patients Eighteen patients were treated with, 10 with idiopathic hypothalamic hypogonadism and eight with Kallmann's syndrome, for 9.3 ± 1.4 months. Their mean (± SD) age at the beginning of was 21.1 ± 3.0 years, and their mean testicular volume was 3.0 ± 2.3 ml. Four patients had previously had orchidopexy because of unilateral cryptorchism. Their mean testosterone concentrations were 1.3 ± 0.6 nmol/1. Their basal and stimulated luteinizing hormone (LH) concentrations were 3.0 ± 1.0 and 12.2 ± 7.8 IU/1, respectively, and basal and stimulated concentrations of follicle stimulating hormone (FSH) were 1.2 ± 0.3 and 2.9 ± 1.9 IU/1. Eighteen patients were treated with gonadotrophins, nine with idiopathic hypothalamic hypogonadism and nine with Kallmann's syndrome, for 14.4 ± 7.3 months. Their mean age at the beginning of was 23.6 ± 7.3 years, and their mean testicular volume was 3.6 ± 3.0 ml. Five patients had previously had orchidopexy because of unilateral cryptorchism. Their mean concentrations of testosterone were 1.2 ± 0.8 nmol/1, basal and stimulated LH 2.2 ± 1.1 and 8.2 ±5.1 IU/1 respectively, and basal and stimulated FSH 1.2 ± 0.7 and 2.3 ± 1.0 IU/1 (Schopohl etal., 1991). was performed with a Zyclomat pump or a BT 2 pump (Ferring, Kiel, Germany) as described previously (Schopohl et al., 1991). Therapy was started with 4 jtg /bolus and dosage was increased stepwise up to 16 /tg /bolus if no pituitary response was seen. Gonadotrophin was started with 3 X 2500 IU human chorionic gonadotrophin (HCG) per week i.m. The HCG dose Oxford University Press 175
2 J.Schopohl 3-18 months n=16 Gonadotrophins 6-27 months n=18 before on before Fig. 1. Testosterone values before and during in each patient of the gonadotrophin releasing hormone ()- and gonadotrophintreated groups. Values before are the mean of two samples, and values on are the means of the last three testosterone values taken during. The shaded area represents the normal range. Closed circles represent the mean value (±SD) in each group. The increase in testosterone was significantly higher with gonadotrophins (P < 0.03). was reduced if oestradiol or testosterone concentrations increased supraphysiologically. The minimal HCG dose needed for maintaining testosterone concentrations within the normal range was 2 X 1000 IU/week. After 2 or 3 months of treatment, 2 x 150 IU weekly doses of human menopausal gonadotrophin (HMG) were added. The HMG dosage was increased up to three and four times per week if testicular growth and the development of sperm count were unsatisfactory. Results Testosterone Concentrations of testosterone increased in all patients of both groups, except in two of them in the group. The mean concentration of testosterone during gonadotrophin was significantly higher (P < 0.03) than during treatment (22.5 ± 8. 1 versus 16.8 ± 5.5 nmol/1). Three patients in the group had values of testosterone between 10.5 and 12 nmol/1, and remained slightly below the normal range (Figure 1). In two patients in the group, no increase in testosterone was observed, due to insufficient compliance, and this was proven by carefully testing pituitary and testicular responses. For this reason, the two patients were excluded from statistical analysis. In the group, testosterone remained in the range seen by Spratt et al. (1986), by whom 22 patients were treated successfully. Mean levels of this steroid in the upper normal range during gonadotrophin were reported by Finkel et al. (1985), Burris et al. (1988b) and Liu et al. (1988a). on Oestradiol An increase in oestradiol concentrations was observed during both treatments (Figure 2). treatment raised the mean value only slightly from 46 ± 22 to 88 ± 59 pmol/1, whereas the increase invoked by the gonadotrophin treatment was significantly more pronounced (P < ) and rose from 41 ± 11 to 179 ± 102 pmol/1, when the highest oestradiol concentrations during this treatment were compared. Oestradiol concentrations were still significantly higher (P < 0.001) after a reduction in the HCG dose (41 ± 11 to 150 ± 70 pmol/1). Only one patient had a supraphysiological oestradiol value of 292 pmol/1 during. No patient of the group developed gynaecomastia, whereas with gonadotrophins eight patients had an exaggerated rise in oestradiol up to 439 pmol/1 and five of them developed gynaecomastia. Elevated oestradiol concentrations persisted in six of these patients after reducing the HCG dosage (Figure 2), and further reduction normalized this steroid but led to a decrease of testosterone to <7 nmol/1. Gynaecomastia improved and oestradiol concentrations declined, but disappeared only when these levels were normalized. Levels of testosterone were > 35 nmol/1 in all patients during the time period involving the highest concentration levels of oestradiol. There are limited amounts of data on changes in oestradiol during in men. Liu et al. (1988a) observed a supraphysiological increase in two out of five patients after 12 months of using a median dose of 30 fig /pulse, which also led to elevated LH levels that were probably responsible for the elevated oestradiol. Spratt et al. 176
3 months n = 16 Highest increase Treatment of hypothalamic hypogonadism in males Gonadotrophins After dose reduction 6-27 months n=18 before before on before on Fig. 2. Oestradiol levels before and on from each patient on gonadotrophin releasing hormone () and on gonadotrophin. Values before are the means of two samples. Values in the middle section represent the highest levels of each patient in the gonadotrophin group during. Values during in the left and right sections respectively are the means of the last three concentrations of oestradiol obtained during the of each patient in the and gonadotrophin groups. The shaded area represents the normal range. Closed circles are the mean value in each group (±SD). The increase in oestradiol was significantly higher with gonadotrophins (P < 0.001). Two patients with lack of compliance (Schopohl etal., 1991). 0) E vol lar 3.O CO 12" months n = 16 (n) patients Gonadotrophins 6-27 months n = 18 r h8 1 6.i *o Qi V) «J ere 4 2 (0-2 fe L o before on before on Fig. 3. Individual increases in testicular volume of each patient of both groups. Numbers in parentheses give patients with the indicated testicular increase. Testicular increase was significantly higher in the gonadotrophin releasing hormone () group (P < 0.001). Two patients with lack of compliance (Schopohl et al., 1991). 177
4 J.Scbopohl , o E " O O u «4. '5 CO 0" 6 9 Months Fig. 4. Monthly testicular growth (ATV/month) in the patients treated with gonadotrophin releasing hormone () and gonadotrophins (Gn). The numbers above the curve and below the gonadotrophin curve represent the number of patients treated at the indicated time points. Testicular growth occurred significantly faster in the group. (1986) described a small increase, not exceeding the normal range in any patient. In three out of 11 patients treated with gonadotrophins, Liu et al. (1988a) described elevated concentrations of oestradiol in some men, although mean levels were only slightly elevated when compared to the five patients treated with. Bums et al. (1988b) observed supraphysiological oestradiol concentrations in seven out of 22 patients treated with HCG. The cause of the higher oestradiol and testosterone concentrations during gonadotrophin is probably testicular overstimulation. This might be an equivalent to the ovarian overstimulation that is observed in women after gonadotrophin, although it has less clinical importance in men than in women. Testicular volume and testicular growth Testicular size increased significantly in both groups (Figure 3). The increase of testicular volume in the -treated patients (the mean increase was 8.1 ± 2.0 ml) was significantly higher (P < 0.001) than in patients treated with gonadotrophins (mean increase of 4.8 ± 1.8 ml) (Figure 3). With, an increase in testicular volume of 8 ml or more occurred in ten patients, whereas only one patient given gonadotrophin showed an enlargement of 8 ml. All others had smaller increases in testicular size (Figure 3). Similar increases of testicular growth were reported by Spratt et al. (1986) after treatment, and by Ley and Leonard (1985) and Burns et al. (1988b) after gonadotrophin treatment. Liu et al. (1988b) observed an important further rise in testicular growth in four patients previously treated with gonadotrophins. In another report, Liu et al. (1988a) reported no significant difference in testicular volume after or gonadotrophins after 2 years of treatment; this was probably due to lack of compliance in some patients given. The testes grew more rapidly during the first 6 months of. During, the growth rate was maximal in the second month of treatment, at 1.5 ± 0.9 ml per month, 178 I 12j "o 8. o «(0 'I Gonadotrophin Initial testicular volume (ml) Fig. 5. Correlation of the initial testicular volume and maximal testicular volume during (above) and gonadotrophin treatment (below). 100-, Vo (n=14) Gonadotrophins (n = 17) Fig. 6. Percentage of positive sperm counts during treatment. The mean time to the initiation of spermatogenesis was significantly shorter (P < 0.02) in the gonadotrophin releasing hormone () group as compared to the gonadotrophin group (12 ± 1.6 versus 20 ± 2.3 months) (Schopohl et al., 1991). 12
5 and in the fourth month of gonadotrophin treatment at 0.7 ± 0.5 ml per month (Figure 4). Comparisons of growth rates over 15 months showed a significantly faster growth in the group (P < 0.001). Significant correlations were found between the initial testicular volume and the maximal testicular volume in both groups. The correlation coefficient in the group was 0.65 (P < 0.01) and in the gonadotrophin group 0.82 (P < 0.001) (Figure 5). This observation confirms the findings of Spratt et al. (1986) and Burris et al. (1988b). Sperm count Sperm counts were performed in 14 patients of the group and in 17 patients of the gonadotrophin group. During pulsatile, sperm counts ranging from 1.5 to 14 X 10 6 spermatozoa/ml were achieved after 9.7 ± 5.6 months (range 4 18 months) in ten patients (71 %). During gonadotrophin treatment, eight patients (47%) reached a positive sperm count ranging from 2 to 26 x 10 6 /ml after 14.9 ± 7.2 months (range 4-27 months). No correlation was found between the elevated concentrations of oestradiol and a failure to induce spermatogenesis. Spratt et al. (1986) reported sperm counts > 1 X 10 6 /ml in 55 % of their patients treated with, with a treatment period ranging from 4 to 21 months (mean 16 ± 2.7 months). In addition, the remaining 45% of patients had sperm counts of < 1 X 10 6 /ml with a period of ranging from 4 to 33 months. Only 42% of their patients with a pre-therapeutic testicular volume of < 3 ml had sperm counts >1 X 10 6 /ml. Burris et al. (1988b) reported positive sperm counts in 68% of their HCG-treated patients, but only 32% had sperm values > 1 X 10 6 /ml; the duration of treatment ranged from 6 to 78 months (mean 20.1 ± 4.4 months). None of their patients with a pre-therapeutic testicular volume of < 3 ml achieved sperm counts of > 1 X 10 6 /ml. However, this limit may be arbitrary because the same authors published data (Burris et al., 1988a) showing that sperm counts had been < 1 x 10 6 /ml in 16% of men who later succeeded in establishing pregnancy. Ley and Leonard (1985) observed positive sperm counts in seven out of eight patients, of whom only one had a pre-therapeutic testicular volume >3 ml. In five patients, sperm counts were > 1 x 10 6 /ml with a period of ranging from 5 to 24 months (mean 13.6 ± 1.8 months). The mean duration of treatment until positive sperm counts were achieved was 12 ± 1.6 months for -treated patients, and 20 ± 2.3 months in those given gonadotrophins; this difference was significant (P < 0.02) (Figure 6). In the group, seven out of 10 (70%) patients with an initial testicular volume <3 ml had a positive sperm count, whereas only three out of 10 (30%) given gonadotrophins had evidence of spermatogenesis. The mean time until the development of a positive sperm count was 13.5 ± 1.8 (±SE) months in the group and 25.8 ± 0.8 months in the gonadotrophin group (P < 0.001). Two patients achieved pregnancy with their spouses, and two children were delivered. In the other patients, pregnancy was not a desired goal at the time of. Liu et al. (1988a) did not observe a more rapid initiation of spermatogenesis during when compared with gonadotrophin treatment. This observation may have arisen due Treatment of hypothalamic hypogonadism in males to the small number of patients treated with for > 1 year (four patients), and due to a significant age difference between their and gonadotrophin-treated patients. Conclusion produces a more rapid initiation of spermatogenesis than gonadotrophin treatment, especially in patients with a testicular volume of 3 ml or less before. No differences occurred in induction of spermatogenesis using either form of. does not lead to elevated concentrations of oestradiol and gynaecomastia, which are frequently observed during gonadotrophin. Patients treated with require good compliance and technical understanding, because they have to manage most of the technical part of the by themselves. This is not necessary when patients are treated with gonadotrophins. Gonadotrophin remains therefore an effective alternative treatment when patients with idiopathic hypothalamic hypogonadism are not able or willing to carry an infusion pump for a year or more. References Burris,A.S., Clark,R.V., Vantman,D.J. and Sherins.R.J. (1988a) A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin. Fertil. Steril., 50, Burris,A.S., Rodbard,J.W., Winters,S.J. and Sherins,R.J. (1988b) Gonadotropic in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J. Clin. Endocrinol. Metab., 66, Finkel.D.M., Phillips,J.L. and Snyder,PJ. (1985) Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N. Engl. J. Med., 313, Hofrrnan,A.R. and Crowley,W.F. (1982) Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropinreleasing hormone. N. Engl. J. Med., 307, Ley.S.B. and Leonard,J.M. (1985) Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. J. Clin. Endocrinol. Metab., 61, Liu.L., Banks,M., Barnes,K.M. and Sherins.R.J. (1988a) Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of in men with isolated hypo-gonadotropic hypogonadism. J. Clin. Endocrinol. Metab., 67, Liu,L., Chaudhari.N., Corle.D. and Sherins,R.J. (1988b) Comparison of pulsatile subcutaneous gonadotropin-releasing hormone and exogenous gonadotropins in the treatment of men with isolated hypogonadotropic hypogonadism. Fertil. Steril, 49, Morris,D.V., Adeniyi-Jones,R., Wheeler,M., Sonksen.P. and Jacobs,H.S. (1984) The treatment of hypogonadotrophic hypogonadism in men by the pulsatile infusion of luteinising hormonereleasing hormone. Clin. Endocrinol., 21, Schopohl,J., Mehltretter,G., von Zumbusch,R., Eversmann,T. and von Werder,K. (1991) Comparison of gonadotropin-releasing hormone and gonadotropin in male patients with idiopathic hypothalamic hypogonadism. Fertil. Steril, 56, Spratt,D., Finkelstein,J.S., O'Dea,L.S.L., Badger.T.M., Rao.P.N., Campbell,J.D. and Crowley.W.F. (1986) Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med., 105,
Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism*
- FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Vol. 56, No, 6, December 1991 Printed on acid-free paper in U.S.A. Comparison of gonadotropin-releasing hormone and gonadotropin
More informationEUROPEAN JOURNAL OF ENDOCRINOLOGY (1998) 139 Gonadotropin or GnRH treatment in hypogonadal men 299 The patients with hypothalamic disorders (group I)
European Journal of Endocrinology (1998) 139 298 303 ISSN 0804-4643 Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism:
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationHCG (human chorionic gonadotropin); Novarel Pregnyl (chorionic gonadotropin); Ovidrel (choriogonadotropin alfa)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.09 Subject: HCG Page: 1 of 5 Last Review Date: June 19, 2015 HCG Powder, Novarel, Pregnyl, Ovidrel
More informationORIGINAL ARTICLE. Open Access
(2017) 19, 1 6 2017 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Male Fertility Open Access ORIGINAL ARTICLE Pulsatile gonadotropin releasing hormone therapy is
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationfor months until the diagnosis were confirmed 86 were IHH and the other 47 were CDP. Repeated triptorelin stimulating tests were conducted in 9
ACTA ACADEMIAE MEDICINAE SINICAE 100730 010-65295073 wsheyan@vip.sina.com LHRH IHH CDP 133 IHH 86 CDP 47 14 24 ~ 48 9 IHH 13 CDP 1 - - LH LH IHH CDP IHH LH 1. 9 ± 1. 2 U /L CDP LH 13. 7 ± 8. 3 U /L P
More informationArticle Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic hypogonadism
RBMOnline - Vol 15. No 2. 2007 156-160 Reproductive BioMedicine Online; www.rbmonline.com/article/2798 on web 14 June 2007 Article Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic
More informationMedicine. Efficacy and Outcome Predictors of Gonadotropin Treatment for Male Congenital Hypogonadotropic Hypogonadism
Medicine OBSERVATIONAL STUDY Efficacy and Outcome Predictors of Gonadotropin Treatment for Male Congenital Hypogonadotropic Hypogonadism A Retrospective Study of 223 Patients Zhaoxiang Liu, MD, Jangfeng
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationLong-Term Administration of Gonadotropin-Releasing Hormone in Men with Idiopathic Hypogonadotropic Hypogonadism
Long-Term Administration of Gonadotropin-Releasing Hormone in Men with Idiopathic Hypogonadotropic Hypogonadism A Model for Studies of the Hormone's Physiologic Effects DANIEL I. SPRATT, M.D.; JOEL S.
More informationSelect patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate
Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate Scott J. Whitten, M.D., a Ajay K. Nangia, M.D., c and Peter N. Kolettis, M.D. b a Division of Reproductive
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
More informationART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
More informationThe reproductive system
The reproductive system THE OVARIAN CYCLE HORMONAL REGULATION OF OOGENSIS AND OVULATION hypothalamic-pituitary-ovary axis Overview of the structures of the endocrine system Principal functions of the
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationOligogenicity. MHH Male Hypogonadotropic hypogonadism MHH MHH MHH MHH MHH MRI. hcg. GnRH MHH PROK MHH. GnRH FSH LH T PRL
MHH Male Hypogonadotropic hypogonadism MHH MHH MHH Kallmann KAL FGFR PROK MHH GnRH Oligogenicity MHH MHH MHH MRI hcg GnRH hcg LH hcg T LH FSH GnRH GnRH MHH LH FSH LH FSH LH T PRL MHH / hcg T FSH FSH hmg
More information15) Presenting Problems in Reproductive Disease Dr. Taha
Testicular & Breast Disorders in Male Hypogonadism Hypogonadism can refer to either: 15) Presenting Problems in Reproductive Disease Dr. Taha 1. The failure of the testes to produce adequate testosterone
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationIndications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men
Review Article Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men John Alden Lee, Ranjith Ramasamy Department of Urology, University of
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationPrimary and secondary amenorrhoea
BRITISH MEDICAL JOURNAL VOLUME 294 28 MARCH 1987 815 Clinical Aalgorithms Primary and secondary amenorrhoea S FRANKS Amenorrhoea, which is usually defined as no periods for six months or more, occurs in
More informationThe reproductive lifespan
The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary
More informationTreatment of Oligospermia with Large Doses of Human Chorionic Gonadotropin
Treatment of Oligospermia with Large Doses of Human Chorionic Gonadotropin A Preliminary Report S. J. GLASS, M.D., and H. M. HOLLAND, M.D. BEFORE discussing gonadotropic therapy of oligospermia, it is
More informationAromatase Inhibitors in Male Infertility:
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism? BEATRIZ UGALDE, PHARM.D. H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1 03 NOVEMBER 2017 PHARMACOTHERAPY ROUNDS Disclosures No conflicts
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationPubertal evaluation of adolescent boys with -thalassemia major and delayed puberty
Pubertal evaluation of adolescent boys with -thalassemia major and delayed puberty Hala Saleh Al-Rimawi, M.D., F.R.C.P., a Mohammad Fayez Jallad, M.D., M.R.C.O.G., b Zouhair Odeh Amarin, M.D., F.R.C.O.G.,
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationAssisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.03 Subject: Synarel Page: 1 of 5 Last Review Date: September 15, 2016 Synarel Description Assisted
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationHormones of brain-testicular axis
(Hormone Function) Hormones of brain-testicular axis anterior pituitary drives changes during puberty controlled by GnRH from hypothalamus begins to secrete FSH, LH LH targets interstitial endocrinocytes
More informationUrinary Testosterone Response to Human Chorionic Gonadotropin
Urinary Testosterone Response to Human Chorionic Gonadotropin Evaluation of Male Patients with Hypogonadotropic Hypogonadism BRUCE L. FARISS, M.D.,* GERARD M. CERCHIO, M.D.,t and VINCENT C. D1 RAIMONDO,
More informationAsimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2
Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist
More informationThe Effect of Clomiphene Citrate Male Infertility
The Effect of Clomiphene Citrate Male Infertility. tn RAYMOND C. MELLINGER, M.D., and ROBERT J. THOMPSON, M.D. CLOMIPHENE CITRATE, an analog of the nonsteroidal estrogen TACE,* has proved effective in
More informationManish Banker. Declared receipt of grants; member of a company advisory board, board of director or similar group
Manish Banker Nova IVI Fertility Pulse Women's Hospital Gujarat, India Declared receipt of grants; member of a company advisory board, board of director or similar group The Indian point of view Manish
More informationThe Usefulness of GnRH and hcg Testing for the Differential Diagnosis of Delayed Puberty and Hypogonadotropic Hypogonadism in Prepubertal Boys
The Usefulness of GnRH and hcg Testing for the Differential Diagnosis of Delayed Puberty and Hypogonadotropic Hypogonadism in Prepubertal Boys Naoko SATO 1), Noriyuki KATSUMATA 1), Reiko HORIKAWA 2) and
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationREPRODUCTION & GENETICS. Hormones
REPRODUCTION & GENETICS Hormones http://www.youtube.com/watch?v=np0wfu_mgzo Objectives 2 Define what hormones are; Compare and contrast the male and female hormones; Explain what each hormone in the mail
More informationHd Hydroxylase. Cholesterol. 17-OH Pregnenolne DHEA Andrstendiol. Pregnenolone. 17-OH Progestrone. Androstendione. Progestrone.
PATHOPHISIOLOGY OF SEX HORMONES R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty CHOLESTEROL IS THE PRECURSOR OF STERIOD HORMONES Cholesterol Pregnenolone 17-OH 17βHSD Pregnenolne DHEA
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationChapter 14 Reproduction Review Assignment
Date: Mark: _/45 Chapter 14 Reproduction Review Assignment Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Use the diagram above to answer the next question.
More informationAnimal Reproduction. Reproductive Cyclicity. # lectures for cumulative test # 02 book 12. Reproductive cyclicity: terminology and basic concepts
Animal Reproduction JP Advis DVM, Ph.D. Bartlett Hall, Animal Sciences, Cook, (732) 932-9240, advis@aesop.rutgers.edu 15 Course website: rci.rutgers.edu/~advis Material to be covered: About lecture Meetings
More informationEndocrine part one. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy
Endocrine part one Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy HORMONES Hormones are chemicals released by a cell or a gland
More informationGONAL-F THE COMPLEX PROCESS OF FERTILITY HORMONE DEFICIENCIES CAN LEAD TO INFERTILITY PROBLEMS WHAT IS GONAL-F? HCP FACT SHEET
HCP FACT SHEET GONAL-F GONAL-f (recombinant follitropin alfa) is prescribed to supplement or replace naturally occurring folliclestimulating hormone (FSH), an essential hormone to treat infertility in
More informationThe Journal of Veterinary Medical Science
Advance Publication The Journal of Veterinary Medical Science Accepted Date: 1 Jun 01 J-STAGE Advance Published Date: Jun 01 Theriogenology (Note) Therapeutic effects of oral clomiphene citrate in dogs
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationDifferent follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation
Human Reproduction vol.8 no.9 pp. 1387-1391, 1993 Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation LJ.M.Duijkers 1 ' 4, H.M.Vemer 1, J.M.G.HoUanders 1, W.N.P.Willemsen
More informationGonadal function after combination chemotherapy
Archives of Disease in Childhood, 12, 7, -21 Gonadal function after combination chemotherapy for Hodgkin's disease in childhood E WHITEHEAD, S SHALET, P H ORRIS JONES, C G BEARDWELL, AND D P DEAKIN Christie
More informationGenetics of Hypogonadism. François Pralong Division of Endocrinology Lausanne University Hospital
Genetics of Hypogonadism François Pralong Division of Endocrinology Lausanne University Hospital The Gonadotrope Axis GnRH LH FSH Sexsteroids(-) Inhibin/follistatin (+) Activin (+) Single Gene Mutations
More informationGONADOTROPHIN (LUTEINISING)- RELEASING HORMONE AND ANALOGUES (GnRH OR LHRH)
GONADOTROPHIN (LUTEINISING)- RELEASING HORMONE AND ANALOGUES (GnRH OR LHRH) Naturally occurring hormone, produced by the hypothalamus and transferred to the anterior pituitary gland in the hypophyseal
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationLH and FSH. Women. Men. Increased LH. Decreased LH. By Ronald Steriti, ND, PhD 2011
LH and FSH By Ronald Steriti, ND, PhD 2011 Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are gonadotropins that stimulate the gonads - the testes in males, and the ovaries in females.
More informationGUIDELINES ON THE INVESTIGATION AND TREATMENT OF MALE INFERTILITY
GUIDELINES ON THE INVESTIGATION AND TREATMENT OF MALE INFERTILITY G. Dohle (chairman), A. Jungwirth and W. Weidner. Eur Urol 2002;42(4):313-322 Eur Urol 2004;46(5):555-558 1. Introduction Infertility is
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationFirst you must understand what is needed for becoming pregnant?
What is infertility? Infertility means difficulty in becoming pregnant without using contraception. First you must understand what is needed for becoming pregnant? Ovum from the woman to combine with a
More informationAdvanced age, poor responders and the role of LH supplementation. C. Alviggi University Federico II, Naples, Italy
Advanced age, poor responders and the role of LH supplementation C. Alviggi University Federico II, Naples, Italy LH serum level (IU/L) 20.0 15.0 10.0 5.0 0.0 LH levels during spontaneous and stimulated
More informationReproductive Hormones
Reproductive Hormones Male gonads: testes produce male sex cells! sperm Female gonads: ovaries produce female sex cells! ovum The union of male and female sex cells during fertilization produces a zygote
More informationModel Answer. M.Sc. Zoology (First Semester) Examination Paper LZT 103 (Endocrinology)
Model Answer M.Sc. Zoology (First Semester) Examination-2013 Paper LZT 103 (Endocrinology) Section A 1. (i) d (ii) b (iii) b (iv) c (v) c (vi) a (vii) c (viii) a (ix) d (x) b Section B Q.2 Answer Hormonal
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Fertavid 50 IU/0.5 ml solution for injection Fertavid 75 IU/0.5 ml solution for injection Fertavid 100 IU/0.5 ml solution for
More informationLH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
More informationMICROWELL ELISA LUTEINIZING HORMONE (LH) ENZYMEIMMUNOASSAY TEST KIT LH ELISA. Cat # 4225Z
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationTHE STIMULATION AND PROLONGED MAINTENANCE OF SPERMATOGENESIS BY HUMAN PITUITARY GONADOTROPHINS IN A PATIENT WITH HYPOGONADOTROPHIC HYPOGONADISM
THE STIMULATION AND PROLONGED MAINTENANCE OF SPERMATOGENESIS BY HUMAN PITUITARY GONADOTROPHINS IN A PATIENT WITH HYPOGONADOTROPHIC HYPOGONADISM F. I. R. MARTIN Endocrine Clinic, Boyal Melbourne Hospital,
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of GONAL-f. This scientific discussion has been updated until 1 July 2004. For information on changes after
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationPACKAGE INSERT PREGNYL. (chorionic gonadotropin for injection, USP) 10,000 units/vial. Human Gonadotropin
PACKAGE INSERT PREGNYL (chorionic gonadotropin for injection, USP) 10,000 units/vial Human Gonadotropin Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 Date of Revision: July 26,
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationIMPORTANT: PLEASE READ
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION PUREGON (follitropin beta) This leaflet is part III of a three-part Product Monograph published when PUREGON was approved for sale in Canada and is
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationLIE ASSAY OF GONADOTROPIN in human blood is one of the most important
Changes in Human Serum FSH Levels During the Normal Menstrual Cycle MASAO IGARASHI, M.D., JUNJI KAMIOKA, M.D., YOICHI EHARA, M.D., and SEIICHI MATSUMOTO, M.D. LIE ASSAY OF GONADOTROPIN in human blood is
More informationMALE INFERTILITY & SEMEN ANALYSIS
MALE INFERTILITY & SEMEN ANALYSIS DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and mitigate potential
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationDidactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
More informationClinical Policy: Infertility Therapy Reference Number: CP.CPA.261 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.CPA.261 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationThe New England Journal of Medicine ADULT-ONSET IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM A TREATABLE FORM OF MALE INFERTILITY.
ADULT-ONSET IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM A TREATABLE FORM OF MALE INFERTILITY LISA B. NACHTIGALL, M.D., PAUL A. BOEPPLE, M.D., FRANÇOIS P. PRALONG, M.D., AND WILLIAM F. CROWLEY, JR., M.D. ABSTRACT
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationRafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant
More informationIsolated follicle-stimulating hormone deficiency in men: successful long-term gonadotropin therapy*
FERTILITY AND STERILITY Copyright c 1984 The American Fertility Society Printed in U.SA. Isolated follicle-stimulating hormone deficiency in men: successful long-term gonadotropin therapy* Ahmed A.-K.
More informationReproductive System. Testes. Accessory reproductive organs. gametogenesis hormones. Reproductive tract & Glands
Reproductive System Testes gametogenesis hormones Accessory reproductive organs Reproductive tract & Glands transport gametes provide nourishment for gametes Hormonal regulation in men Hypothalamus - puberty
More informationGUIDELINES FOR THE INVESTIGATION AND TREATMENT OF MALE INFERTILITY
GUIDELINES FOR THE INVESTIGATION AND TREATMENT OF MALE INFERTILITY G.R. Dohle, Z. Kopa, A. Jungwirth, T.B. Hargreave. Eur Urol 2002;42(4):313-322 Eur Urol 2004;46(5):555-558 Definition Infertility is the
More informationEvaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS
Evaluation and Management of Pituitary Failure Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS Conflict of Interest None Objectives Diagnostic approach
More informationLow dose of cyproterone acetate and testosterone enanthate for contraception in men
Human Reproduction vol.13 no.5 pp.1225 1229, 1998 Low dose of cyproterone acetate and testosterone enanthate for contraception in men M.Cristina Meriggiola 1,3, William J.Bremner 2, Antonietta Costantino
More information